We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+7.45%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$4.72B
AUM Growth
+$323M
Cap. Flow
+$92.3M
Cap. Flow %
1.96%
Top 10 Hldgs %
16.89%
Holding
1,475
New
127
Increased
594
Reduced
562
Closed
97

Sector Composition

Rank Sector Weight
1 Technology 17.88%
2 Financials 10.44%
3 Healthcare 10.37%
4 Industrials 8.75%
5 Consumer Discretionary 7.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
USFR icon
1251
WisdomTree Floating Rate Treasury Fund
USFR
$18.1B
$209K ﹤0.01%
+4,165
New +$210K
EVV
1252
Eaton Vance Limited Duration Income Fund
EVV
$1.06B
$209K ﹤0.01%
21,243
+51
+0.2% +$512
TYG
1253
Tortoise Energy Infrastructure Corp
TYG
$1.09B
$208K ﹤0.01%
+7,065
New +$222K
SCHB icon
1254
Schwab US Broad Market ETF
SCHB
$43.2B
$207K ﹤0.01%
+12,960
New +$203K
TNL icon
1255
Travel + Leisure Co
TNL
$4.66B
$207K ﹤0.01%
+5,269
New +$213K
EVH icon
1256
Evolent Health
EVH
$348M
$206K ﹤0.01%
+6,360
New +$201K
ERIC icon
1257
Ericsson
ERIC
$32.2B
$206K ﹤0.01%
35,170
+14,227
+68% +$81.2K
IRDM icon
1258
Iridium Communications
IRDM
$5.02B
$206K ﹤0.01%
+3,322
New +$199K
JAZZ icon
1259
Jazz Pharmaceuticals
JAZZ
$15.9B
$205K ﹤0.01%
1,398
AUB icon
1260
Atlantic Union Bankshares
AUB
$6.02B
$204K ﹤0.01%
5,824
BGB
1261
Blackstone Strategic Credit 2027 Term Fund
BGB
$499M
$204K ﹤0.01%
19,153
-7,148
-27% -$78K
PLRX icon
1262
Pliant Therapeutics
PLRX
$64.4M
$204K ﹤0.01%
+7,667
New +$218K
WIW
1263
Western Asset Inflation-Linked Opportunities & Income Fund
WIW
$505M
$199K ﹤0.01%
21,800
PGF icon
1264
Invesco Financial Preferred ETF
PGF
$677M
$199K ﹤0.01%
13,680
-783
-5% -$12K
NRK icon
1265
Nuveen New York AMT-Free Quality Municipal Income Fund
NRK
$901M
$198K ﹤0.01%
18,719
UMH
1266
UMH Properties
UMH
$1.29B
$198K ﹤0.01%
13,363
+190
+1% +$3.12K
ENLC
1267
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
$191K ﹤0.01%
17,595
ECAT icon
1268
BlackRock ESG Capital Allocation Term Trust
ECAT
$1.49B
$189K ﹤0.01%
12,096
+37
+0.3% +$540
PRME icon
1269
Prime Medicine
PRME
$527M
$186K ﹤0.01%
15,118
+1,106
+8% +$18K
MFC icon
1270
Manulife Financial
MFC
$73.9B
$185K ﹤0.01%
10,074
-44,275
-81% -$842K
IONQ icon
1271
IonQ
IONQ
$13.6B
$185K ﹤0.01%
30,000
PSP icon
1272
Invesco Global Listed Private Equity ETF
PSP
$232M
$182K ﹤0.01%
3,604
-630
-15% -$32.7K
BCAT icon
1273
BlackRock Capital Allocation Term Trust
BCAT
$1.65B
$180K ﹤0.01%
11,865
-8
-0.1% -$119
WIA
1274
Western Asset Inflation-Linked Income Fund
WIA
$185M
$178K ﹤0.01%
20,600
-5,400
-21% -$47.5K
FAX
1275
abrdn Asia-Pacific Income Fund
FAX
$599M
$177K ﹤0.01%
11,083
+7,416
+202% +$123K

Similar funds

Oppenheimer & Co's Q1 2023 Portfolio in Review

As of Q1 2023, Oppenheimer & Co held 1,475 positions worth $4.72B, up 7.3% from $4.39B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Oppenheimer & Co's Q1 2023 filing shows 127 new, 594 increased, 562 reduced and 97 closed positions. Its largest new stake was FT Vest US Equity Deep Buffer ETF December: 306,411 shares worth $9.8M. The largest sale was Oneok, an estimated $9.41M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

  • Oppenheimer & Co's largest Q1 2023 buy was FT Vest US Equity Deep Buffer ETF December: 306,411 shares worth $9.8M.
  • Oppenheimer & Co added most to iShares Treasury Floating Rate Bond ETF in Q1 2023, an estimated $18.3M increase.
  • Oppenheimer & Co's biggest Q1 2023 reduction was Oneok, cutting an estimated $9.41M.
  • Oppenheimer & Co fully exited State Street SPDR Portfolio S&P 500 Value ETF in Q1 2023, selling an estimated $5.18M.
  • Oppenheimer & Co's ten largest holdings make up 17% of its $4.72B portfolio in Q1 2023.
  • Oppenheimer & Co opened 127 new positions and closed 97 in Q1 2023.
  • Oppenheimer & Co's portfolio value rose 7.3% quarter-over-quarter to $4.72B.

Based on Oppenheimer & Co's 13F filing for Q1 2023, filed 10 May 2023.